Establishing Correlation Between Non-invasive Pulmonary Blood Pressure Readings and Swan-Ganz Results - Trial NCT04509089
Access comprehensive clinical trial information for NCT04509089 through Pure Global AI's free database. This phase not specified trial is sponsored by Suremedix Ltd and is currently Completed. The study focuses on Congestive Heart Failure. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Suremedix Ltd
Timeline & Enrollment
N/A
Dec 01, 2020
Mar 01, 2021
Primary Outcome
Pressure waveform
Summary
Pulmonary hypertension (PH) is prognostic indicator in heart failure patients for poor
 outcome, however, it is challenging for monitoring. The current study is designed to explore
 whether data generated using Suremedix Device including a pump and non-invasive sensors
 including, chest motion sensor, photoplethysmography (PPG), and Electrocardiography (ECG),
 can be used to identify detectable oscillations that are correlated with the mean, the
 diastolic and the systolic pressure values of the pulmonary artery, as measured using the
 gold-standard Swan-Ganz method.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04509089
Device Trial